| 0 (0%) | 06-28 18:07 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 74.51 | 1-year : | 76.92 |
| Resists | First : | 63.79 | Second : | 65.86 |
| Pivot price | 62.62 |
|||
| Supports | First : | 60.45 | Second : | 50.29 |
| MAs | MA(5) : | 62.31  |
MA(20) : | 63.21 |
| MA(100) : | 59.57 |
MA(250) : | 56.87 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 34.2 |
D(3) : | 34.4 |
| RSI | RSI(14): 46.2 |
|||
| 52-week | High : | 65.86 | Low : | 51.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AXS ] has closed above bottom band by 40.4%. Bollinger Bands are 36.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 62.83 - 63.06 | 63.06 - 63.25 |
| Low: | 61.05 - 61.34 | 61.34 - 61.58 |
| Close: | 62.14 - 62.59 | 62.59 - 62.96 |
Sat, 10 Aug 2019
AveXis Receives FDA Approval of Zolgensma, a Gene Therapy, for Spinal Muscular Atrophy for Patients Under Two ... - Cure SMA
Fri, 13 Apr 2018
About - Novartis
Mon, 09 Apr 2018
Novartis to Acquire Gene Therapy Provider AveXis for $8.7B in Cash - HIT Consultant
Mon, 09 Apr 2018
AveXis Enters Agreement to be Acquired by Novartis AG for $8.7 billion - GlobeNewswire
Mon, 09 Apr 2018
AveXis, ALS Gene Therapy AVXS-301 to Be Bought by Novartis for $8.7B - ALS News Today
Mon, 09 Apr 2018
Novartis inks $8.7B AveXis buyout to build gene therapy unit - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 85 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 94.5 (%) |
| Shares Short | 944 (K) |
| Shares Short P.Month | 1,020 (K) |
| EPS | 4.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 55.25 |
| Profit Margin | 6.6 % |
| Operating Margin | -6.6 % |
| Return on Assets (ttm) | 1.2 % |
| Return on Equity (ttm) | 7.5 % |
| Qtrly Rev. Growth | 2.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 66.59 |
| EBITDA (p.s.) | 7.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1,260 (M) |
| Levered Free Cash Flow | -10,950 (M) |
| PE Ratio | 15.44 |
| PEG Ratio | 0.3 |
| Price to Book value | 1.12 |
| Price to Sales | 0.93 |
| Price to Cash Flow | 4.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|